GA NCORP

NCORP Trials

Connect® Myeloid Disease Registry

Status
Active
Cancer Type
Cancer-Related Syndrome
Leukemia
Myelodysplastic Syndromes (MDS)
Trial Phase
Eligibility
18 Years and older, Male and Female
Study Type
Other
NCD ID
NCT01688011
Protocol IDs
Connect® MDS/AML Registry (primary)
Study Sponsor
Celgene Corporation

Summary

The purpose of the Connect® Myeloid disease registry is to provide unique insights into
treatment decisions and treatment patterns as they relate to clinical outcomes of patients
with myeloid diseases in routine clinical practice. This disease registry will also evaluate
molecular and cellular markers that may provide further prognostic classification which may
or may not be predictive of therapy and clinical outcomes.

Objectives

This Disease Registry will collect data on patient characteristics, treatment patterns and
clinical outcomes. The objective is to describe how patients with myeloid diseases are
treated; and to build a knowledge base regarding the effectiveness and safety of first line
and subsequent treatment regimens in both community and academic settings. Enrolled patients
will receive treatment and evaluations for their disease according to the standard of care
and routine clinical practice at each study site. All treatments that patients receive for
their disease will be recorded, including initial treatment and any subsequent therapy. Data
on treatment outcomes, including response rates as measured by the treating physician,
evidence of progression, survival, and patient-reported outcomes will be collected quarterly
on the electronic CRF.

Treatment Sites


 
For a complete listing of all trial sites in Georgia, please visit GeorgiaCancerInfo.org